SLC5A2 and hydrops fetalis: The safety profile was consistent with the known class effect.<h4>Conclusion</h4>In patients with HFpEF and a recent HF hospitalization, these exploratory findings suggest that SGLT2 inhibitors may provide cardiovascular benefit.